Articles On Immutep (ASX:IMM)

  Immutep (ASX:IMM; NASDAQ:IMMP) announced that their Efti, a soluble LAG-3 protein, in Combination with KEYTRUDA®, generates excellent overall survival benefit in patients with metastatic non-small cell lung cancer. In response, Marc Voigt...

Immutep (ASX:IMM) reveals its drug Efti, in combination with Keytruda, generates significant survival benefits for those suffering from metastatic non-small cell lung cancer At lower protein PD-L1 expression, survival rates increase betw...

The Immutep Ltd (ASX: IMM) share price is jumping on Monday. In morning trade, the ASX All Ords biotech stock is up 16% to 32 cents. Why is this ASX All Ords stock racing higher? Investors have been buying the company's shares today follow...

Aussie shares to slump once again after heavy selloff on Wall Street Traders are wary of developments in the Middle East Magnificent Seven to report their earnings this week   Aussie shares are poised to open lower again after another sel...

Welcome to the start of the week. ASX futures were down 65 points (0.95 per cent) heading into 8:30 AEDT. The US had another red session on Friday with the S&P 500 down 1.26 per cent; and the NASDAQ down 1.53 per cent. The Dow and R...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Global Health announces deal with Fujitsu Australia Althea raises $5.32m in sale and leaseback deal Immutep to present data from TACTI-002 in key international forum   Global Health signs with Fujitsu Global Health (ASX:GLH), a provider o...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Consumers are becoming more cautious due to rising living costs, but UBS analysts believe this doesn’t indicate an immediate drop in spending, as they note a slight improvement in future interest rate expectations; however, sticky inflation...

The ASX experienced continued declines at midday, with banking stocks being particularly affected. This drop was triggered by the recent hawkish statements from the US Federal Reserve. At noon, the S&P/ASX 200 is 1.01 per cent lower at...

21 Sep 2023 - A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Vulcan Energy Resources (ASX:VUL) and Australian Gold and Copper (ASX:AGC).

  Immutep (ASX:IMM; NASDAQ:IMMP) announces the regulatory authorisation of “efti”, which is the Company’s proprietary soluble LAG-3 protein, for the use in clinical trials across multiple European countries. In response, Marc Voigt, CEO of...

ASX to open lower again on Thursday The US Fed held rates steady, but opened the door for one more hike in 2023 Klaviyo (NYSE: KVYO) made its listing debut overnight   Australian shares are poised to track Wall Street and open lower once...

Immutep (ASX:IMM) has announced the regulatory authorisation of eftilagimod alpha manufactured at commercial 2,000L scale for clinical trials across multiple countries, including Germany, Belgium, Denmark, and the UK.

Futures are predicting the market will open slightly lower this morning, despite yesterday’s decision by the US Federal Reserve to hold interest rates steady. The US Fed did state that it could consider another rate hike before the end o...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AMX)) - Aerometrex ((ART)) - Airtasker ((BBT)) - BlueBet Holdings ((CMW)) - Cromwell Property ((DTC)) - Damstra Holdings ((GHY)) - Gold Hydrogen ((IMM)) - Immutep ((LVH)...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

ASX health stocks fall 2.4% in the past five days in line with broader markets Mesoblast crashes more than 50% after US FDA rejects a key product  ImpediMed falls after calls for board spill with discontent following cap raise Healthcare...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Australian clinical-stage biotechnology company Immutep (ASX:IMM) says it has received positive scientific advice from the European Medicines Agency for the continued development of its soluble LAG-3 protein and first-in-class MHC C...

31 Jul 2023 - Immunotherapy company Immutep has released its Quarterly Activities report, which highlights significant progress in late-stage and registrational trials.

Immutep Limited (ASX:IMM; NASDAQ:IMMP), a biotechnology firm specialising in novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announced its Quarterly Activities Report and Appendix 4C for Q4 FY23. The report...

Australian retail sales experienced a 0.8% decline last month, as reported by the Australian Bureau of Statistics. This result came as a surprise to markets, which had anticipated a steady performance for June following a robust 0.7% gain i...

  First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma Immutep (ASX:IMM; NASDAQ:IMMP) announced that the first patient has been dosed in the Chemotherapy-free Combination Phase II Trial Ta...

The ASX looks set to stoop lower for the last session of the week. Investors are warned to keep an eye open for today’s release of the latest retail sales figures as the rest of Australia prepares for next week’s RBA interest rate decisi...

28 Jul 2023 - A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Pointerra (ASX:3DP) and Zeus Resources (ASX:ZEU).

ASX healthcare shares are currently underperforming ASX 200 shares, but over the longer term, they’ve grown twice as fast. The S&P/ASX 200 Index (ASX: XJO) is up 7.1% over the past year, while the S&P/ASX 200 Health Care Index (AS...

The All Ordinaries Index (ASX: XAO) is up a healthy 4% in 2023, while ASX All Ords share Immutep Ltd (ASX: IMM) has surged 17% over this same time. And the ASX biotech company could have more potential outperformance to come. Here’s w...

The Bubs Australia Ltd (ASX: BUB) share price is ending the week deep in the red. In morning trade, the embattled infant formula company’s shares are down 11% to 16 cents. Why is the Bubs share price sinking? Investors have been hitting...

ASX 200 benchmark climbs 0.65% despite a sour lead-in from Wall Street and Europe. Real Estate sector banks solid wins after shopping centres put on a big day.  Forrestania Resources hits 162% on thick pegmatite news, but the ASX has asked...

  Marc Voigt – Executive Director & CEO – Immutep (ASX:IMM) is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 immunotherapy for cancer and autoimmune diseases.

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

20 Jun 2023 - Immutep Limited (ASX:IMM), a clinical-stage biotechnology company focusing on LAG-3 immunotherapies for cancer and autoimmune diseases, has received a new patent from…

The ASX 200 climbed 0.86% today, after the RBA said it wants you all to get fired. Energy stocks climb 1.94% after I dared to turn my heater on this morning. Brightstar is thiiiis close to actual gold production, up 30% today as a result....

A couple of ASX lithium shares have been catching the eye on Tuesday with some strong gains. Let’s take a look and see what’s getting investors excited today: Leo Lithium Ltd (ASX: LLL) The Leo Lithium share price is up 9% to $1.17. Th...

Austco Healthcare wins St Paul’s Hospital in Canada worth $7.4m Next Science announced a new CEO AVITA Medical and Genetic Signatures announce new CFOs   Digital health company Austco Healthcare (ASX:AHC) surged by as high as 30% this mor...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another gain. The benchmark index is currently up 0.25% to 7,180 points. Four ASX shares that are climbing more than most today are listed below. Here’s why...

I believe that the two ASX shares I’m going to write about in this article have the potential to deliver total returns of over 100% in the next three years. While small businesses naturally have more room to grow compared to large busine...

The infectious diseases space is one area that could be interesting for ethical investors An ASX company that already has a product in the market is Starpharma Stockhead reached out to Starpharma CEO, Jackie Fairley   Throughout history,...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

ASX All Ords retail share Universal Store Holdings Ltd (ASX: UNI) crashed by almost 25% in just two weeks and three company directors have enthusiastically bought the dip. One took a ‘go hard or go home’ approach and ploughed more than $1...

All stocks, no matter how well they perform in the long run, will have short-term dips. That’s why it’s imperative to not get distracted by these fluctuations.  In fact, if the quality of the business’ future prospects hasn’t changed then...

The Adairs Ltd (ASX: ADH) share price suffered a big sell-off last week – it fell around 15% on Friday. It’s down 28% from 22 May 2023 and it has dropped 45% from 1 February 2023. The ASX All Ordinaries Index (ASX: XAO) share has been...

If you have room for some new portfolio additions in June, then it could be worth considering the three ASX growth shares listed below. Here’s what you need to know about these buy-rated shares: Aristocrat Leisure Limited (ASX: ALL) The...

Several new health-focused funds joined the biotech’s register including Platinum.

If you’re searching for a passive income boost, then you may want to check out the ASX dividend stocks listed below. Analysts have named these dividend stocks as buys and tipped them to provide very large yields in the near term. Hereâ€...

ASX retail shares are falling amid news today of a 5.75% hike to the minimum wage and concern among investors about the rising cost of living now affecting retail sales in 2023. Earlier today the Fair Work Commission announced a 5.75% bum...